Terms: = Breast cancer AND JAK3, L-JAK, 3718, ENSG00000105639, P52333, JAKL, JAK-3, LJAK, JAK3_HUMAN AND Treatment
17 results:
1. Integrated Safety Analysis of Ritlecitinib, an Oral jak3/TEC Family Kinase Inhibitor, for the treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program.
King B; Soung J; Tziotzios C; Rudnicka L; Joly P; Gooderham M; Sinclair R; Mesinkovska NA; Paul C; Gong Y; Anway SD; Tran H; Wolk R; Zwillich SH; Lejeune A
Am J Clin Dermatol; 2024 Mar; 25(2):299-314. PubMed ID: 38263353
[TBL] [Abstract] [Full Text] [Related]
2. Metformin inhibits the tumor-promoting effect of low-dose resveratrol, and enhances the anti-tumor activity of high-dose resveratrol by increasing its reducibility in triple negative breast cancer.
Cheng T; Wang C; Lu Q; Cao Y; Yu W; Li W; Liu B; Gao X; Lü J; Pan X
Free Radic Biol Med; 2022 Feb; 180():108-120. PubMed ID: 35038549
[TBL] [Abstract] [Full Text] [Related]
3. Identification of differentially expressed lncRNAs and mRNAs in luminal-B breast cancer by RNA-sequencing.
Yuan CL; Jiang XM; Yi Y; E JF; Zhang ND; Luo X; Zou N; Wei W; Liu YY
BMC Cancer; 2019 Dec; 19(1):1171. PubMed ID: 31795964
[TBL] [Abstract] [Full Text] [Related]
4. 21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for breast cancer Patients with Positive Lymph Nodes.
Tong Y; Wu J; Huang O; He J; Zhu L; Chen W; Li Y; Chen X; Shen K
Sci Rep; 2019 Sep; 9(1):13123. PubMed ID: 31511599
[TBL] [Abstract] [Full Text] [Related]
5. Application of Highly Immunocompromised Mice for the Establishment of Patient-Derived Xenograft (PDX) Models.
Okada S; Vaeteewoottacharn K; Kariya R
Cells; 2019 Aug; 8(8):. PubMed ID: 31412684
[TBL] [Abstract] [Full Text] [Related]
6. SOCS3 overexpression enhances ADM resistance in bladder cancer T24 cells.
Li MZ; Lai DH; Zhao HB; Chen Z; Huang QX; Situ J
Eur Rev Med Pharmacol Sci; 2017 Jul; 21(13):3005-3011. PubMed ID: 28742207
[TBL] [Abstract] [Full Text] [Related]
7. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
[TBL] [Abstract] [Full Text] [Related]
8. MEK inhibition prevents tumour-shed transforming growth factor-β-induced T-regulatory cell augmentation in tumour milieu.
Hossain DM; Panda AK; Chakrabarty S; Bhattacharjee P; Kajal K; Mohanty S; Sarkar I; Sarkar DK; Kar SK; Sa G
Immunology; 2015 Apr; 144(4):561-73. PubMed ID: 25284464
[TBL] [Abstract] [Full Text] [Related]
9. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.
De Mattos-Arruda L; Weigelt B; Cortes J; Won HH; Ng CKY; Nuciforo P; Bidard FC; Aura C; Saura C; Peg V; Piscuoglio S; Oliveira M; Smolders Y; Patel P; Norton L; Tabernero J; Berger MF; Seoane J; Reis-Filho JS
Ann Oncol; 2014 Sep; 25(9):1729-1735. PubMed ID: 25009010
[TBL] [Abstract] [Full Text] [Related]
10. Effects of 5-fluorouracil and gemcitabine on a breast cancer cell line (MCF-7) via the JAK/STAT pathway.
Uluer ET; Aydemir I; Inan S; Ozbilgin K; Vatansever HS
Acta Histochem; 2012 Nov; 114(7):641-6. PubMed ID: 22172707
[TBL] [Abstract] [Full Text] [Related]
11. Benzoxathiol derivative BOT-4-one suppresses L540 lymphoma cell survival and proliferation via inhibition of jak3/STAT3 signaling.
Kim BH; Min YS; Choi JS; Baeg GH; Kim YS; Shin JW; Kim TY; Ye SK
Exp Mol Med; 2011 May; 43(5):313-21. PubMed ID: 21499010
[TBL] [Abstract] [Full Text] [Related]
12. A comprehensive model that explains the regulation of phospholipase D2 activity by phosphorylation-dephosphorylation.
Henkels KM; Peng HJ; Frondorf K; Gomez-Cambronero J
Mol Cell Biol; 2010 May; 30(9):2251-63. PubMed ID: 20176813
[TBL] [Abstract] [Full Text] [Related]
13. MS-1020 is a novel small molecule that selectively inhibits jak3 activity.
Kim BH; Oh SR; Yin CH; Lee S; Kim EA; Kim MS; Sandoval C; Jayabose S; Bach EA; Lee HK; Baeg GH
Br J Haematol; 2010 Jan; 148(1):132-43. PubMed ID: 19793252
[TBL] [Abstract] [Full Text] [Related]
14. EGF-induced MMP-9 expression is mediated by the jak3/ERK pathway, but not by the jak3/STAT-3 pathway in a SKBR3 breast cancer cell line.
Kim S; Choi JH; Lim HI; Lee SK; Kim WW; Cho S; Kim JS; Kim JH; Choe JH; Nam SJ; Lee JE; Yang JH
Cell Signal; 2009 Jun; 21(6):892-8. PubMed ID: 19385051
[TBL] [Abstract] [Full Text] [Related]
15. Structure-based design of novel anticancer agents.
Uckun FM; Sudbeck EA; Mao C; Ghosh S; Liu XP; Vassilev AO; Navara CS; Narla RK
Curr Cancer Drug Targets; 2001 May; 1(1):59-71. PubMed ID: 12188892
[TBL] [Abstract] [Full Text] [Related]
16. Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.
Sudbeck EA; Liu XP; Narla RK; Mahajan S; Ghosh S; Mao C; Uckun FM
Clin Cancer Res; 1999 Jun; 5(6):1569-82. PubMed ID: 10389946
[TBL] [Abstract] [Full Text] [Related]
17. Minimal breast cancer. Clinical characteristics and treatment results.
Semiglazov VF; Pavlov KA; Orlov AA
Neoplasma; 1983; 30(3):365-9. PubMed ID: 6306493
[TBL] [Abstract] [Full Text] [Related]
